1. Home
  2. AKRO vs CRC Comparison

AKRO vs CRC Comparison

Compare AKRO & CRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • CRC
  • Stock Information
  • Founded
  • AKRO 2017
  • CRC 2014
  • Country
  • AKRO United States
  • CRC United States
  • Employees
  • AKRO N/A
  • CRC N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • CRC Oil & Gas Production
  • Sector
  • AKRO Health Care
  • CRC Energy
  • Exchange
  • AKRO Nasdaq
  • CRC Nasdaq
  • Market Cap
  • AKRO 3.6B
  • CRC 4.2B
  • IPO Year
  • AKRO 2019
  • CRC N/A
  • Fundamental
  • Price
  • AKRO $46.20
  • CRC $57.56
  • Analyst Decision
  • AKRO Strong Buy
  • CRC Strong Buy
  • Analyst Count
  • AKRO 8
  • CRC 12
  • Target Price
  • AKRO $80.38
  • CRC $65.00
  • AVG Volume (30 Days)
  • AKRO 978.3K
  • CRC 1.0M
  • Earning Date
  • AKRO 11-07-2025
  • CRC 11-04-2025
  • Dividend Yield
  • AKRO N/A
  • CRC 2.69%
  • EPS Growth
  • AKRO N/A
  • CRC 205.84
  • EPS
  • AKRO N/A
  • CRC 7.21
  • Revenue
  • AKRO N/A
  • CRC $3,624,000,000.00
  • Revenue This Year
  • AKRO N/A
  • CRC $20.98
  • Revenue Next Year
  • AKRO N/A
  • CRC N/A
  • P/E Ratio
  • AKRO N/A
  • CRC $7.98
  • Revenue Growth
  • AKRO N/A
  • CRC 60.00
  • 52 Week Low
  • AKRO $21.34
  • CRC $30.97
  • 52 Week High
  • AKRO $58.40
  • CRC $60.41
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 51.07
  • CRC 73.01
  • Support Level
  • AKRO $41.80
  • CRC $48.84
  • Resistance Level
  • AKRO $45.44
  • CRC $58.41
  • Average True Range (ATR)
  • AKRO 1.97
  • CRC 1.83
  • MACD
  • AKRO 0.06
  • CRC 0.76
  • Stochastic Oscillator
  • AKRO 74.58
  • CRC 91.12

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About CRC California Resources Corporation

California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.

Share on Social Networks: